新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » CRO/CMO » 中国泰格入股美国Frontage Laboratories

中国泰格入股美国Frontage Laboratories

来源:生物谷 2014-05-12 08:40

2014年5月11日讯 /生物谷BIOON/ --最近总部在中国杭州的合约研究机构泰格公司宣布已经和美国宾夕法尼亚州合约研究机构Frontage Laboratories达成合作协议,花费5000万美元入股Frontage Laboratories公司。根据协议,泰格公司将获得Frontage在美国早期研发领域积累的宝贵经验。这一协议将使得泰格公司能够进一步在中国、亚洲以及美国市场扩大优势。而Frontage Laboratories公司目前在中国上海的机构仍将独立运行。

成立于2004年的泰格公司在经过十年的不懈努力后已经成为了中国最大的合约研究机构之一。公司目前在中国和亚洲市场有超过1000名员工,承担着许多生物技术公司的外包研究业务。(生物谷Bioon.com)

详细英文报道:

Chinese CRO Tigermed is buying its way into the U.S., signing a deal to trade $50.3 million for a majority stake in Pennsylvania's Frontage Laboratories.

Under the cash arrangement, Tigermed will take up a stateside operation with capabilities in bioanalysis, early-phase studies and drug development, tapping Frontage's experience in biopharma work from discovery to postmarketing trials. Frontage, which also has an operation in Shanghai, will continue to operate independently, the companies said, with Song Li staying on board as CEO.

For the Hangzhou-headquartered Tigermed, Frontage's focus on early development and chemistry manufacturing controls are an ideal complement to its late-stage expertise, CEO Xiaoping Ye said. And for the U.S. CRO, joining Tigermed will expose it to a larger client base in China and Asia at large, Li said.

"The two companies' track records in trial execution, combined geographic reach, and shared vision on quality delivery will position our combination as a global one-stop source for clinical development activities," Li said in a statement. "This partnership enables Frontage to offer its existing clients a more comprehensive solution for clinical trial support, from Phases I through IV."

Since its founding in 2004, Tigermed has grown into one of China's largest pharma outsourcing outfits, now employing about 1,000 people across its home country and Asia.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库